Journal: bioRxiv
Article Title: Modeling cell-cell interactions to advance drug discovery in Idiopathic Pulmonary Fibrosis
doi: 10.64898/2026.01.29.702646
Figure Lengend Snippet: a-b: Nintedanib IC50 values from two IPF patients calculated by COL1A1 expression changes ( a ) and organoid surface area reduction ( b ). c-d: SB-431542 IC50 values with two IPF patients calculated by COL1A1 expression changes ( c ) and organoid surface area reduction ( d ). e-g : effect of Nintedanib (40nM, IC50 value for IPF1) on IPF1 secreted biomarkers: e . MMPs and TIMPs, f . TGFβ1 and TGFβ2, and g . chemokines and cytokines. h-j : effect of SB-431542 (60nM, IC50 value for IPF1) on IPF1 secreted biomarkers: h . MMPs and TIMPs, i . TGFβ1 and TGFβ2, and j . chemokines and cytokines. P values are calculated from technical replicates (n=3) for each biological replicate using one way ANOVA for each biomarker. ***: P<0.001, **: P<0.01, *: P<0.05.
Article Snippet: To examine whether our IPF-Fib with iAT2 I73T/tdT cell co-culture organoid model will respond to the FDA approved therapy Nintedanib (Medchem Express, cat. BIBF 1120) and the TGFβ inhibitor SB-431542 (Alk5 inhibitor) (Medchem Express, cat. HY-10431), we tested these drugs in the organoid co-cultures using fibroblasts derived from two individual IPF patients in combination with the iAT2 I73T/tdT cells.
Techniques: Expressing, Biomarker Discovery